EUVIMEDEUVIMED entdecken
Crossref

Height benefit of GnRH agonists after age 8 in a Portuguese cohort of central precocious puberty

Carolina Castro iD, Filipa Espada, Ana Luísa Leite, Ana Antunes, Brígida Robalo, Daniela Amaral, Elisa Galo, Sofia Castro, Sofia Ferreira, Catarina Limbert

Clinical Endocrinology · 2023

DOI: 10.1111/cen.14884 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, 2023. Verfasst von Carolina Castro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Paediatric Endocrinology, Deparment of Paediatrics, Hospital Pedro Hispano, Porto, Matosinhos, Portugal. Hauptthemen laut MEDLINE: Gonadotropin-Releasing Hormone, Puberty, Precocious. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Ipsen Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Idiopathic central precocious puberty (iCPP) is common in paediatric endocrinology. Gonadotropin‐releasing hormone agonists (GnRHa) are safe, but the effect on final height and the ideal timing for treatment remains controversial. This study aims to assess the effectiveness of GnRHa on growth outcomes in girls with iCPP treated before and after the age of 8 years old. Design and Patients This retrospective longitudinal study evaluated data from Portuguese girls with iCPP who completed treatment between 2010 and 2021.

Measurements

Auxological and clinical characteristics were compared according to age at treatment onset.

Results

A cohort of 134 girls with iCPP, was divided into early treatment (ET) (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gonadotropin-Releasing HormonePuberty, PrecociousAdultChildFemaleHumansBody HeightLongitudinal StudiesPortugalRetrospective Studies

Stichwörter der Autor:innen

GnRH agonistsfinal adult heightgrowth improvementidiopathic central precocious pubertytarget height

Substanzen

Gonadotropin-Releasing Hormone

Autor:innen und Institutionen

  • Unit of Paediatric Endocrinology, Deparment of Paediatrics, Hospital Pedro Hispano, Porto, Matosinhos, Portugal.
  • Department of Paediatrics, Hospital CUF Porto, Porto, Portugal.
  • Unit of Paediatric Endocrinology and Diabetes, Department of Paediatrics, Centro Hospitalar de Vila Nova de Gaia/Espinho, Espinho, Portugal.
  • Unit of Paediatric Endocrinology, Department of Paediatrics, Hospital de Braga, Braga, Portugal.
  • Unit of Paediatric Endocrinology, Department of Paediatrics, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal.
  • Clínica Universitária de Pediatria, Department of Paediatrics, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

ORCID-Profile: Carolina Castro

Förderung

  • Ipsen Fund

Zitieren

APA

Castro, C., Espada, F., Leite, A. L., Antunes, A., Robalo, B., Amaral, D., Galo, E., Castro, S., Ferreira, S., & Limbert, C. (2023). Height benefit of GnRH agonists after age 8 in a Portuguese cohort of central precocious puberty. Clinical Endocrinology. https://doi.org/10.1111/cen.14884

Vancouver

Castro C, Espada F, Leite AL, Antunes A, Robalo B, Amaral D, et al. Height benefit of GnRH agonists after age 8 in a Portuguese cohort of central precocious puberty. Clinical Endocrinology. 2023. doi:10.1111/cen.14884

BibTeX
@article{Castro2023,
  author = {Castro, Carolina and Espada, Filipa and Leite, Ana Luísa and Antunes, Ana and Robalo, Brígida and Amaral, Daniela and Galo, Elisa and Castro, Sofia and Ferreira, Sofia and Limbert, Catarina},
  title = {Height benefit of GnRH agonists after age 8 in a Portuguese cohort of central precocious puberty},
  journal = {Clinical Endocrinology},
  year = {2023},
  doi = {10.1111/cen.14884}
}
Kostenlos starten →